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Short minutes of the meeting
In a first presentation, professor Yves Beguin (CHU 
Sart Tillman, Liège) gave an overview of the benefits 
of treatment with erythropoiesis-stimulating agents 
(ESAs) in terms of reduction of the need for trans-
fusions and increase in quality of life, as well as on 
the different possible dosage schedules with different 
products (thrice weekly (TIW), once weekly (QW), 
once every 3 weeks (Q3W)) and the demonstration 
that dose doubling (2x standard dose) did not provide 
a better response for patients initially not responding 
to standard doses. He went through the pivotal 
trials that led to the original registrations of each 
product. He clarified that on average, two thirds of 
patients seem to respond to therapy. (In the later 
discussion on how many patients do finally benefit 
from treatment with ESA, agreement was reached 
that for patients starting ESA treatment, red blood 
cell (RBC) transfusion can be completely avoided for 
an additional ±30% of patients compared to the 
control groups.) Two factors seem responsible for a 
possible lack of response: inflammation and/or 
functional iron deficiency. Inflammation was shown 
to lead to decreasing Hb levels, and correction of 
functional iron deficiency with iron sucrose 200-
300 mg IV Q2W x 3 doses has shown to lead to a 
faster response, higher response rate, fewer transfusions 
and less ESA use compared to patients not receiving 
IV iron, with 5 clinical studies demonstrating the 
positive effect of the addition of IV iron in these 
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Summary
On July 1st 2009, a panel of experts met with the goal to provide a joint medical opinion 
on the use of erythropoiesis-stimulating agents (ESAs) in chemotherapy-induced anemia 
(CIA), as well as a joint proposal for revised reimbursement criteria in Belgium. The goal is to 
provide a clear and workable guidance on the use of ESAs in their registered indication: 
chemotherapy induced anemia in cancer patients. An overview of participating experts 
can be found in Table 1. 
(Belg J Med Oncol 2010;4:57-64)
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patients. On the topic of safety of these agents, 
professor Beguin mentioned the trend of increased 
hypertension (mostly however observed in the chronic 
kidney disease (CKD) patients), increased risk of 
thrombotic events and the lack of any evidence for 
tumour growth. On the long term safety in terms of 
overall survival (OS) or progression free survival (PFS), 
an exhaustive number of studies was discussed, 
starting with the study of Littlewood et al. that, in 
2001, published results that seemed to demonstrate 
a trend towards increased overall survival for patients 
receiving epoetin alpha versus the control group. 
This study led to several other studies trying to con-
firm such finding in different settings of anemia in 
cancer patients, with very different and sometimes 
conflicting outcomes. 
Results from several studies in Head and Neck 
cancer (s.a. ENHANCE, DAHANCA, RTOG-99-03) 
in patients treated with radiotherapy and given ESAs 
with the aim to increase Hb levels to sometimes as 
high as 14-15 g/dl, found a clear detrimental 
effect on local control and overall survival for the 
group treated with ESAs. Also in a study in patients 
with cervical cancer receiving both chemotherapy 
and radiotherapy as their cancer treatment, the ESA 
treated groups did worse than the control group. 
This lead to professor Beguin’s conclusion that ESAs 
are clearly not indicated for use in patients receiving 
radiotherapy only. 
In lymphoid tumours, a study by Hedenus et al. 
in a mixed tumour setting of several lymphoid 
malignancies showed a worse outcome on OS but 
identical PFS. Large studies in diffuse large B-cell 
lymphoma (DLBCL) (LNH03-6B) and Hodgkin’s 
disease (GHSG-H15) and a smaller study in (acute) 
lymphoblastic lymphoma/Burkitt’s lymphoma (ALL- 
LL-BL) (Mattiuzzi) showed no significant differences 
in outcome. The conclusion seems to be that in lym-
phoid tumours results should be considered as neutral.
In breast cancer, conflicting results were recorded in 
different studies. A study published by Leyland- 
Jones et al. in 2005 (BEST) in metastatic breast cancer 
and the preliminary results of the PREPARE study in 
neo-adjuvant setting presented by Untch reported a 
worse outcome for ESA-treated patients, whereas other 
studies such as reported by Aapro et al. in 2008 
(BRAVE), Chang et al. in 2005 (EPO-CAN-17) and 
Moebus et al. in 2007 did not find any outcome diffe-
rence in terms of OS or PFS.
Also in non-small cell lung cancer (NSCLC), con-
flicting results were reported: a study by Wright et 
al. 2007 (EPO-CAN-20) in the setting of metastatic 
lung cancer reported worse outcome, and another 
study (EPO-GER-22) reported no significant diffe-
rences. In SCLC, the 2 studies reporting outcomes: 
(N93-004) by Grote 2005 and (2001-0145) by Pirker 
2008 reported no significant differences in OS, with 
completely overlapping survival curves.
In the setting of anemia of cancer (without any chemo- 
therapy or radiotherapy), a study by Smith et al. 
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 EU Label EORTC ESMO ASCO/ASH US Label
 EMEA/CHMP Guidelines Guidelines Guidelines  FDA
Initiation of symptomatic anemia  Hb 9-11 g/dl Hb ≤10 g/dl approaching or has Hb ≤10 g/dl
ESA (eg. Hb ≤10 g/dl) based on anemia-  fallen below 10 g/dl 
  related symptoms
Mild anemia? - may be considered  Hb 10-12.0 g/dl, Hb 10-12 g/dl, start declining Hb <12,
  in selected asympto-  treatment can be determined by clinical decision to use epo
  matic patients,   considered in case circumstances or wait until <10
  Hb 11-11.9 g/dl to of symptoms  should be deter-
  prevent further decline   mined by clinical 
     circumstances
Target Hb 10-12 g/dl, A sus- about 12 g/dl Hb should not near 12 g/dl Hb exceeding level
 tained Hb >12 g/dl   exceed 12 g/dl  needed to avoid
 should be avoided    transfusion
Non- epo A+B: doule dose if ‘no recommendation dose doubling. dose escalations as discontinue if no
responders?  <1 g/dl in 4 weeks, if that dose escalation  Continuation beyond per label. Discontinue response after 8
 <1 g after 8 weeks: dis- should be general  6-8 weeks in the  if no response after weeks or if
 continue, darbepoetin: approach’ absence of response 6-8 weeks transfusions still
 dose doubling not  is not beneficial  required
 recommended, if no 
 clinical response after 
 9 weeks, discontinue  
Dose - if Hb >2g/m or  individualize treatment = idem EU label dose reductions as -  if Hb >1 g/2w or
adjustments    >12 g/dl → reduce  when reaching target  per label and recom-    >12 or 11 g/dl
   by 25 or 50% (increasing dose interval  mended when Hb rise    → reduce by 25
 - if Hb >13 g/dl →  or titration to lowest   >1 g/2w or exceeds    or 40%
   discontinue and restart  effective maintenance  11 g/dl -  if Hb >12 g/dl
   until <12 g/dl dose      → discontinue 
        and restart until 
        <11 g/dl, restart 
        at lower dose
Iron  evidence for IV iron iv iron substitution iron repletion is iron therapy recom-
  when iron depleted  when iron deficiency indicated mended if serum
  IV iron to be reserved    ferritin <100 mcg/L
  for patients with abso-   or serum trans-
  lute or functional iron   ferrin saturation 
  deficiency   <20%
Safety 4.4 Special warnings  increased risk: Decreased survival or complete section on Boxed Warning:
 and precautions:….. TE events x 1.6 and PFS seen in several discussion of individual - ESAs shortened
 “… in some clinical hypertension randomized studies trials and ODAC   OS or PFS in some
 situations blood trans-  but design aimed at briefings 2004 and   studies …
 fusion should be the  Hb >12 g/dl and in- 2007 - use lowest dose
 preferred treatment for  cluded patients with    needed
 management of anemia  baseline Hb >10 g/dl  - use only for
 in patients with cancer.  TE: risk increased by    anemia due to
 The decision to use  67%. Use to be care-    chemotherapy
 ESA should be based  fully considered in  - ESA not indicated
 on a benefit-risk  patients at high TE    when the antici-
 assessment, …”  risk …    pated outcome is
 Including factors, such  In patients treated with    cure
 as type of tumour,  curative intent, ESAs  - discontinue
 stage, degree of ane-  should be used with    following comple-
 mia, life-expectancy,  caution. (D)    tion of a chemo
 environment and      course
 patients preference.
EMEA=European Medicines Agency, CHMP=Committee for Medicinal Products for Human Use, FDA=Food and Drug Administration, OS=overall 
survival, PFS=progression-free survival.
Table 2. Comparison of current erythropoiesis-stimulating agent (ESA) labels and guidelines.
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(2001-0103) reported a worse outcome on OS 
for ESA-treated patients, confirming former results 
of a study published by Wright et al. (2007), and 
demonstrating that ESAs should not be used in the 
‘anemia of cancer’ (AoC) setting.
After shortly demonstrating the relationship between 
Hb levels and QoL improvements and the effectiveness 
of ESAs in reducing the need for RBC transfusions, 
Professor Vansteenkiste (UZ Leuven, campus Gast-
huisberg) presented a schematic analysis of the 
different meta-analyses as published by Bohlius et al. 
in 2005, 2006 and 2009. In the first meta-analysis, 
published in 2005, and comprising trials that studied 
the treatment of CIA, a significant positive effect of 
ESAs on OS with a hazard ratio (HR)=0.81 (0.67-
0.99) was reported. With the observation of the 
proven benefit of ESAs in treatment of CIA, and the 
observation that anemia is a negative prognostic 
factor, the hypothesis was generated that prevention 
of anemia would improve prognosis, and several 
studies were set up in different settings: prevention 
of anemia during chemotherapy (‘high Hb studies’), 
prevention of anemia during radiotherapy (‘RT’- 
studies) and studies on normalization of anemia in 
patients not receiving chemotherapy (‘AoC’-studies). 
In the most recent pharmacovigilance update (2008) 
8 out of 59 RCTs gave rise to some safety concern; 
4 in ‘high Hb’ setting (BEST, PREPARE, Thomas et al., 
Hedenus et al.), 2 ‘AoC’ studies (Wright et al., Smith 
et al.) and 2 RT studies (Henke et al., Dahanka et al.). 
The second meta-analysis published by Bohlius et al. 
in 2006 therefore comprised a mixture of studies in 
both treatment as well as prevention of anemia in 
different settings (not only CIA), and the HR for OS 
turned towards 1.08 (0.99-1.18) in the disadvantage 
of ESA-treated patients. Interesting to note that for 
the studies performed between 2002 and 2005, the 
HR was reported to be 1.16. In the most recent, patient 
level meta-analysis for studies in chemotherapy- 
induced anemia (CIA), still mixing the treatment 
and prevention approaches, the HR for OS became 
1.04 (0.97-1.11), with most recent trials again 
responsible for the more negative outcomes as 
demonstrated by the subgroup analysis published 
by Bohlius et al. (HR for mortality-on-study in all 
chemotherapy treated patients was 1.10 (0.98-1.24) 
compared to a HR for mortality for all patients 
(including patients treated with RT-only and those 
with AoC) of 1.17 (1.06-1.30).
A very recent patient level meta-analysis on all 7 
double-blind, placebo-controlled RCTs with darbe-
poetin for the treatment of CIA, Ludwig et al. (2009) 
reported completely overlapping curves for both OS 
as well as PFS for ESA-treated and control group. 
In summary, professor Vansteenkiste concluded that 
in his opinion the safety signals in terms of outcome 
reported for the settings of AoC, RT and prevention 
or high Hb-level studies should clearly lead to the 
abandoning of use of ESAs in those particular 
settings, whereas meta-analysis results and individual 
studies seem to clearly confirm a positive risk/benefit 
in the registered indication of ‘treatment of CIA’, 
where a proven benefit for the use of ESAs in terms 
of reduction of RBC transfusions and a better QoL 
has also been demonstrated.
The different safety signals from individual studies, 
as well as the meta-analysis results have been 
discussed in specific hearings by Oncologic Drugs 
Advisory Committee (ODAC) in the US and by 
European Medicines Evaluation Agency (EMEA) in 
Europe. As a result, the labels of the different ESA-
products have been updated with appropriately 
revised dosage recommendations and warnings 
covering the different safety signals observed.
Also international guidelines such as the ESMO, 
EORTC and ASH/ASCO practice guidelines on the 
use of ESAs have updated their practice guidelines 
following the availability of new data on the use of 
ESAs (Table 2). 
In a third presentation of the evening, professor 
Van Belle (UZ Gent) presented the current Belgian 
reimbursement criteria in a historic perspective. In 
the current setting, very different criteria are used 
depending on if the chemotherapy includes a 
platinum compound or not. For platinum-based 
chemotherapy settings, the current criteria are very 
unrestrictive, as there is no definition of initiation 
minimal Hb level, nor dosage or duration limitations 
for the use of ESAs in this setting. For non-platinum 
based chemotherapy on the other hand, starting 
and stopping rules have been established, although 
these criteria were not evidence based. In current 
practice, ESA therapy can be initiated for chemo-
therapy-treated patients for whom the Hb level has 
dropped below 11 g/dl in a first starting therapy for 
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4 weeks for solid tumours, and 8 weeks for hemato-
logical tumours. If a Hb response of at least 1 g/dl 
has been observed within these first 4 (or 8) weeks, 
a further 8 weeks of therapy can be reimbursed 
(Table 3 and 4).
Consensus statement
After the exhaustive review of individual studies 
reporting on long term safety, the data of the different 
meta-analyses and the updated labels, guidelines as 
well as current reimbursement criteria, the scene was 
set to open the debate aiming to arrive at a common 
medical opinion by the expert-panel on the practical 
use of ESAs in CIA.
The topics suggested for discussion included the 
following:
• How many and which patients are obtaining benefit?
• When should ESA therapy be initiated? 
• Do we need to make a distinction between plati- 
 num and non-platinum based chemotherapy?
• Which target Hb level to aim for?
• How long needed to evaluate if patient is responder 
 or not? And how to define response?
• Treatment duration? When stop treatment?
• What about dose increases (e.g. dose-doubling) if 
 no response after initial treatment?
• What about iron repletion guidelines?
• What is our advice concerning the potential 
 treatment in an adjuvant or curative setting?
61
Eprex®/Binocrit® NeoRecommon® Aranesp®
Treatment of secondary anemia induced Treatment of secondary anemia induced Treatment of secondary anemia induced
by platinum CT in adult cancer patients by platinum CT in adult patients with solid by platinum CT in adult cancer patients
 tumours 
• Exclusion of other causes of anemia (occult hemorrhage, iron deficiency, hemolysis, …)
• Need for upfront demand to medical advisor
• Reimbursement given for 12 months after authorization of medical advisor
• Possibility of prolongation for 12 months
 → No specific criteria regarding initial Hb level, dose, duration of treatment, …
 → Doubling of dose allowed if the increase in hemoglobin is inadequate
Table 3. Current reimbursement criteria in onco-hemato: platinum based chemotherapy.
   Eprex®/Binocrit® NeoRecommon® Aranesp®
• Secondary anemia patients with solid or hematological tumours treated with CT
• Hb level <11g/dl
• Exclusion of all others of anemia
Initial treatment Dose: 150 IU/kg 3x/week  Dose: 450 IU/kg per week Dose: 2.25 μg/kg per week
   or 450 IU/kg per week  
   Duration: 4 weeks for solid tumours; 8 weeks for hematological tumours
If increase in Hb level ≥1 g/dl without any transfusion after initial treatment
⇓
Continuation of treatment =  Dose: 150 IU/kg 3x/week Dose: 450 IU/kg per week Dose: 2.25 μg/kg per week
8 weeks  or 450IU/kg per week 
• No need for upfront demand to medical advisor
• Keep all information (tumour type, chemotherapy, Hb level, …) at disposition of medical advisor
• Reimbursement maximum 2x per 12 months
Table 4. Current reimbursement criteria in onco-hemato: non-platinum based chemotherapy.
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After ample discussion on these topics, and initially 
hearing several interpretations and points of view, 
the expert panel came to the following consensus 
statement:
ESAs should be used within their approved label, 
meaning, for treatment of CIA, not for prevention 
neither for anemia of cancer nor in radiotherapy-
only-treated patients.  
Within the setting of CIA:
•	 ESA treatment can be initiated in a patient 
showing symptomatic anemia and an Hb level 
that has fallen to at least below 11 g/dl. (symp-
tomatic anemia, <11 g/dl)
•	 The maximal Hb level should be around 12 g/
dl. (maximum = around 12 g/dl)
•	 If Hb level reaches above 13 g/dl or conti-
nuously remains higher than 12, treatment 
should be discontinued, and only reinstated at 
adequately reduced doses after the Hb level has 
lowered to below 12 g/dl. (discontinue if 
above 13 or continuously above 12)
•	 ESAs, once started, should be given for an 
initial treatment period of 6-8 weeks, after 
which response should be evaluated. For 
patients considered responders (obtaining a rise 
in Hb value of at least 1 g/dl after 8 weeks), 
treatment can be further continued as needed 
until maximum 4 weeks after the last chemo-
therapy administration. For non-responders 
(patients not reaching 1 g/dl increase of Hb 
after 8 weeks), treatment should be stopped (a 
former practice of increasing the ESA dosages 
for patients not responding after an initial 8 
weeks of ESA at standard dosage was not con-
sidered good practice, as data did demonstrate 
no benefit by doing so). (Initial treatment for 
6-8 weeks, evaluate response, no response 
= stop treatment, responder: continue if 
needed until a maximum of 4 weeks after last 
chemotherapy administration).
•	 It should be routine practice to evaluate iron 
deficiency in patients considered for ESA treat-
ment by measuring transferrin saturation (Tsat) 
at baseline and during treatment. In case of a 
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Figure 1. Proposed text for reimbursement criteria, Dutch version. 
De specialiteit X (hier Aranesp) wordt vergoed als ze is voorgeschreven door de geneesheerspecialist die verantwoordelijk is voor de 
behandeling en wordt toegediend als ondersteunende therapie bij rechthebbenden, die op het ogenblik van de aanvraag met een 
anti-neoplastische chemotherapie worden behandeld, een symptomatische anemie vertonen en waarbij het hemoglobinegehalte gedaald 
is onder de 11 g/dl (6,87 mmol/l) en na het uitsluiten en behandelen van andere oorzaken van anemie, in één van de volgende doses:
a) in een aanvangsbehandeling:
 een weekdosis van 2,25 µg/kg lichaamsgewicht gedurende een initiële behandelingsperiode van maximum 8 weken;  
 (aanpassen relevante doses voor epo a en b)
b) in een consolidatiebehandeling:
 als na de aanvangsbehandeling zonder tussentijdse transfusie het hemoglobinegehalte met minimum 1 g/dl (0,6245 mmol/l) ten  
 opzichte van de beginsituatie gestegen is, kan een verlenging van de vergoeding van de behandeling toegekend worden.  
 De behandeling met deze specialiteit zal de duur van de verdere chemotherapie met maximaal 4 weken overschrijden.
De behandeling zal erop gericht zijn een maximale Hb-waarde van ongeveer 12 g niet te overschrijden, en dient on-
derbroken indien een waarde van 13 g/dl of een blijvende waarde boven 12 g/dl zou bekomen worden. 
Het verhogen van de gemiddelde weekdosis bepaald in de aanvangsbehandeling is niet toegestaan.
De bewijsstukken die aantonen dat aan de voorwaarden is voldaan en waarin uitdrukkelijk het type tumor, de toegediende anti- 
neoplastische behandeling, het hemoglobinegehalte en in het geval van een consolidatiebehandeling, het hemoglobinegehalte bij start en 
na 8 weken behandeling met deze specialiteit vermeld zijn, moeten door de voorschrijvende arts ter beschikking worden gehouden 
van de adviserend geneesheer.
De machtiging tot vergoeding in deze indicatie kan maximaal 2 maal per 12 maanden verleend worden.
Belgian Journal of Medical Oncology   volume 4, issue 2, 2010
Practice guidelines
Tsat below 20%, IV iron supplementation 
should be administered together with ESA 
treatment, and Tsat monitored during the further 
treatment. (Evaluate iron status by Tsat, if Tsat 
<20% → IV iron sucrose supplementation: 
200-300 mg IV over 1 h Q2W x 3 doses). This 
practice has been shown in 5 separate studies to 
lead to faster response, increased response rate, 
a further reduction of the need for RBC trans-
fusions and a lower total dosage of ESA needed 
to sustain an adequate Hb level.
•	 The panel discussed in depth about their concerns 
regarding the potential negative impact on sur-
vival from the use of ESAs in curative settings, and 
agrees with the most recent recommendations 
by EMEA that state the following: “In view of the 
above, in some clinical situations blood transfusions 
should be the preferred treatment for the manage-
ment of anaemia in patients with cancer. The decision 
to administer recombinant erythropoietins should 
be based on the benefit-risk assessment with the 
participation of the individual patient, which should 
take into account the specific clinical context. Factors 
that should be considered in this assessment should 
include the type of tumour and its stage; the degree 
of anaemia; life-expectancy; the environment in which 
the patient is being treated; and patient preference.” 
(EU-label texts) 
Observing the results of this expert consensus, these 
guidelines are in practice very similar to the ESMO 
recommendations.
Reimbursement proposal
In order to enable the Belgian physicians to apply 
above practice guidelines in a correct manner and 
with the aim to both simplify criteria as well as avoid 
criteria that would enable a use larger than the one 
recommended (see current criteria for platinum- 
treated patients), the panel proposes the following 
criteria to be implemented for Belgian reimburse-
ment of ESAs:
•	 Eligible patient: symptomatic CIA and with a 
Hb level <11 g/dl.
•	 Prior exclusion and correction of all other causes 
63
Figure 2. Proposed text for reimbursement criteria, French version. 
La spécialité X (ici Aranesp) est remboursée si elle est prescrite par le médecin spécialiste responsable du traitement et administrée 
comme thérapie de soutien chez des bénéficiaires qui, au moment de la demande, sont traités avec une chimiothérapie antinéo-
plasique, ont une anémie symptomatique et chez lesquels le taux d’hémoglobine a diminué en dessous de 11 g/dl (6,87 mmol/l), 
après exclusion et traitement d’autres causes d’anémie, en une des doses suivantes:
a) en cas de traitement initial:
 une dose hebdomadaire de 2,25 µg/kg poids corporel pour une période de traitement de maximum 8 semaines; (adaptez 
 dosages pour epo a et b)
b) en cas de traitement de consolidation:
 si après le traitement initial, sans transfusion intermédiaire, le taux d’hémoglobine a augmenté d’au minimum 1 g/dl (0,6245  
 mmol/l) par rapport à la situation de départ, une prolongation de remboursement du traitement peut être accordée. Le traitement 
 avec cette spécialité ne pourra être continué plus de 4 semaines après la dernière administration de la chimiothérapie.
Le traitement aura comme objectif de ne pas dépasser un taux maximal d’hémoglobine aux alentours de 12 g/dl et 
doit être interrompu si le taux d’hémoglobine atteint 13 ou reste constamment au dessus de 12 g/dl.  
Une augmentation de la dose par semaine, comme décrit pour le traitement initial, n’est pas permise.
Les pièces justificatives démontrant que les conditions sont rencontrées et dans lesquelles le type de tumeur, le traitement antinéo-
plasique administré, le taux d’hémoglobine et, en cas de traitement de consolidation, le taux d’hémoglobine au début et après 8 
semaines de traitement avec cette spécialité sont formellement mentionnés, doivent être tenues par le médecin prescripteur à la 
disposition du médecin-conseil.
L’autorisation de remboursement dans cette indication peut être accordée au maximum 2 fois par 12 mois.
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of anemia.
•	 No more distinction in criteria between different 
types of chemotherapy regimens nor tumour 
types (solid or hematological tumours/platinum 
or non-platinum regimens).
•	 Initial treatment: 8 weeks.
•	 Evaluation of response after maximum 8 weeks:
 - If Hb level increased less than 1 g/dl →
  STOP ESA
 - If Hb level increased with 1 g/dl or more: 
  continue further ESA therapy if needed, with 
  a maximal duration of 4 weeks after last 
  chemotherapy administration.
•	 The maximal Hb level should be around 12 g/dl.
•	 No dosage increase versus standard dose allowed. 
(standard dosages in equivalents per week 
mentioned in detailed texts for reimbursement)
•	 Treatment needs to be discontinued if Hb above 
13 or continuously above 12, and reinstated 
when needed. 
•	 Dosages and dosage reductions as per most 
recent labels.
•	 Iron status of the patient should be monitored 
at initiation and during treatment.       
If Tsat <20%: Replenishment by IV administra-
tion of iron sucrose needs to be added to the 
ESA treatment.
An example of (draft) text for reimbursement criteria 
(French and Dutch version) is represented in Figures 
1 and 2 on page 62 and 63.
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Key messages for clinical practice
1. Within the setting of chemotherapy-induced anemia, erythropoiesis-stimulating 
agents (ESAs) should be:
• Initiated with symptomatic anemia, Hb levels <11 g/dl
• The maximum Hb level should be around 12 g/dl
• Discontinued if above Hb level 13 or continuously above 12
2. Initial ESA treatment should be given for 6-8 weeks after which response should 
be evaluated
• No response = stop treatment
• Responder: continue if needed until a maximum of 4 weeks after last chemo-
     therapy administration
3. Iron status should be evaluated by Tsat. If Tsat <20% → IV iron sucrose supple-
mentation: 200-300 mg IV over 1 h Q2W x 3 doses.
